BDX · Becton Dickinson & Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.71B | $5.25B | $5.51B | $5.27B | $5.17B | $4.99B | $5.04B | $4.71B | $4.88B | $4.82B |
| Cost of Revenue | $2.56B | $2.84B | $2.88B | $3.02B | $2.93B | $2.68B | $2.74B | $2.68B | $2.78B | $2.59B |
| Gross Profit | $2.15B | $2.41B | $2.63B | $2.26B | $2.23B | $2.31B | $2.30B | $2.03B | $2.10B | $2.23B |
| R&D | $249.00M | $306.00M | $297.00M | $302.00M | $343.00M | $299.00M | $299.00M | $290.00M | $306.00M | $337.00M |
| SG&A | $1.21B | $1.39B | $1.32B | $1.27B | $1.32B | $1.20B | $1.19B | $1.21B | $1.19B | $1.21B |
| Total Operating Expenses | $4.62B | $4.70B | $4.63B | $4.72B | $4.71B | $4.39B | $4.31B | $4.27B | $4.33B | $4.19B |
| D&A | $567.00M | $614.00M | - | - | $607.00M | - | - | $561.00M | - | - |
| Operating Income | $93.00M | $552.00M | $882.00M | $546.00M | $453.00M | $602.00M | $734.00M | $439.00M | $549.00M | $628.00M |
| Interest Expense | $149.00M | $153.00M | $152.00M | $125.00M | $155.00M | $119.00M | $125.00M | $111.00M | $119.00M | $118.00M |
| Income Tax | $76.00M | $11.00M | $129.00M | $55.00M | $3.00M | $13.00M | $96.00M | $77.00M | $64.00M | $68.00M |
| Net Income | ($311.00M) | $382.00M | $574.00M | $308.00M | $303.00M | $487.00M | $537.00M | $281.00M | $407.00M | $460.00M |
| EPS - Basic | ($1.11) | $1.05 | $1.57 | $0.84 | $0.83 | $1.32 | $1.45 | $0.76 | $1.08 | $1.21 |
| EPS - Diluted | ($1.11) | $1.05 | $1.57 | $0.84 | $0.82 | $1.32 | $1.45 | $0.75 | $1.07 | $1.20 |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $813.00M | $740.00M | $641.00M | $667.00M | $711.00M | $1.72B | $2.35B | $1.18B | $1.42B | $1.98B |
| Accounts Receivable | $2.21B | $2.51B | $2.99B | $3.03B | $2.64B | $3.03B | $2.56B | $2.27B | $2.53B | $2.41B |
| Inventory | $3.36B | $4.08B | $3.89B | $3.72B | $3.86B | $3.84B | $3.23B | $3.30B | $3.27B | $3.66B |
| Accounts Payable | - | - | $1.97B | - | - | $1.90B | - | - | $1.64B | - |
| Current Assets | $8.01B | $9.19B | $9.26B | $8.67B | $8.66B | $10.47B | $10.34B | $8.16B | $8.68B | $9.59B |
| Total Assets | $50.83B | $54.84B | $55.33B | $54.47B | $54.66B | $57.29B | $54.16B | $52.27B | $52.78B | $54.39B |
| Current Liabilities | $8.51B | $8.76B | $8.31B | $7.69B | $7.66B | $8.96B | $7.33B | $7.54B | $6.64B | $7.30B |
| Long-term Debt | $14.71B | $16.92B | $17.62B | $17.67B | $17.44B | $17.94B | $15.99B | $14.09B | $14.74B | $16.01B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $24.13B | $25.28B | $25.39B | $25.24B | $25.20B | $25.89B | $25.65B | $25.33B | $25.80B | $25.69B |
| Retained Earnings | $17.39B | $16.70B | $16.62B | $16.15B | $16.14B | $16.14B | $15.80B | $15.54B | $15.54B | $15.56B |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | $693.00M | - | - | $693.00M | - | - | $855.00M | - | - |
| Investing Cash Flow | - | ($183.00M) | - | - | $204.00M | - | - | ($291.00M) | - | - |
| Financing Cash Flow | - | ($302.00M) | - | - | ($1.93B) | - | - | ($862.00M) | - | - |
| CapEx | - | $108.00M | - | - | $105.00M | - | - | $116.00M | - | - |
| Free Cash Flow | - | $585.00M | - | - | $588.00M | - | - | $739.00M | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 45.7% | 45.9% | 47.8% | 42.8% | 43.2% | 46.2% | 45.7% | 43.1% | 43.1% | 46.4% |
| Operating margin | 2.0% | 10.5% | 16.0% | 10.4% | 8.8% | 12.1% | 14.5% | 9.3% | 11.3% | 13.0% |
| EBITDA margin | 14.0% | 22.2% | - | - | 20.5% | - | - | 21.2% | - | - |
| Net margin | -6.6% | 7.3% | 10.4% | 5.8% | 5.9% | 9.8% | 10.6% | 6.0% | 8.3% | 9.5% |
| Free cash flow margin | - | 11.1% | - | - | 11.4% | - | - | 15.7% | - | - |
| FCF / Net income | - | 1.53 | - | - | 1.94 | - | - | 2.63 | - | - |
| R&D / Revenue | 5.3% | 5.8% | 5.4% | 5.7% | 6.6% | 6.0% | 5.9% | 6.2% | 6.3% | 7.0% |
| SG&A / Revenue | 25.7% | 26.5% | 24.0% | 24.1% | 25.5% | 24.0% | 23.6% | 25.8% | 24.4% | 25.0% |
| Effective tax rate | - | 2.8% | 18.3% | 15.2% | 1.0% | 2.6% | 15.2% | 21.5% | 13.6% | 12.9% |
| Return on assets | -0.6% | 0.7% | 1.0% | 0.6% | 0.6% | 0.9% | 1.0% | 0.5% | 0.8% | 0.8% |
| Return on equity | -1.3% | 1.5% | 2.3% | 1.2% | 1.2% | 1.9% | 2.1% | 1.1% | 1.6% | 1.8% |
| Return on invested capital | 0.2% | 1.3% | 1.7% | 1.1% | 1.1% | 1.3% | 1.5% | 0.9% | 1.2% | 1.3% |
| Liquidity | ||||||||||
| Current ratio | 0.94 | 1.05 | 1.11 | 1.13 | 1.13 | 1.17 | 1.41 | 1.08 | 1.31 | 1.31 |
| Quick ratio | 0.55 | 0.58 | 0.64 | 0.64 | 0.63 | 0.74 | 0.97 | 0.64 | 0.81 | 0.81 |
| Cash ratio | 0.10 | 0.08 | 0.08 | 0.09 | 0.09 | 0.19 | 0.32 | 0.16 | 0.21 | 0.27 |
| Leverage | ||||||||||
| Debt / Equity | 0.61 | 0.67 | 0.69 | 0.70 | 0.69 | 0.69 | 0.62 | 0.56 | 0.57 | 0.62 |
| Debt / Assets | 0.29 | 0.31 | 0.32 | 0.32 | 0.32 | 0.31 | 0.30 | 0.27 | 0.28 | 0.29 |
| Debt / EBITDA | 22.28 | 14.51 | - | - | 16.45 | - | - | 14.09 | - | - |
| Interest coverage | 0.6x | 3.6x | 5.8x | 4.4x | 2.9x | 5.1x | 5.9x | 4.0x | 4.6x | 5.3x |
| Equity multiplier | 2.11 | 2.17 | 2.18 | 2.16 | 2.17 | 2.21 | 2.11 | 2.06 | 2.05 | 2.12 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
| Inventory turnover | 0.76 | 0.70 | 0.74 | 0.81 | 0.76 | 0.70 | 0.85 | 0.81 | 0.85 | 0.71 |
| Days sales outstanding | 171d | 174d | 198d | 210d | 186d | 222d | 185d | 176d | 190d | 183d |
| Days inventory outstanding | 479d | 525d | 494d | 451d | 480d | 523d | 430d | 450d | 430d | 516d |
| Days payable outstanding | - | - | 251d | - | - | 258d | - | - | 216d | - |
| Cash conversion cycle | - | - | 442d | - | - | 487d | - | - | 404d | - |
| Valuation | ||||||||||
| P / E | - | 144.8x | 93.6x | 214.1x | 218.1x | 143.5x | 133.8x | 254.0x | 190.1x | 161.8x |
| P / B | 1.8x | 1.7x | 1.7x | 2.1x | 2.1x | 2.1x | 2.2x | 2.2x | 2.3x | 2.2x |
| P / S | 9.4x | 8.3x | 7.7x | 9.8x | 10.0x | 11.0x | 11.2x | 11.9x | 12.0x | 11.5x |
| EV / EBITDA | 87.9x | 51.3x | - | - | 64.6x | - | - | 68.8x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -10.6% | 1.6% | 10.4% | 4.5% | 9.8% | 2.3% | 4.6% | 2.6% | 5.1% | -3.8% |
| Revenue CAGR (3y) | -0.7% | 4.6% | 5.9% | 1.7% | 1.1% | 0.7% | 0.9% | -4.0% | 8.2% | 4.3% |
| Revenue CAGR (5y) | -0.8% | -0.2% | 7.4% | 4.4% | 4.1% | 2.8% | 3.8% | 2.5% | 2.7% | 2.7% |
| Gross profit growth (YoY) | -4.6% | 7.9% | 14.2% | -2.0% | 10.3% | 9.9% | 3.1% | -5.0% | 1.6% | -3.0% |
| Operating income growth (YoY) | -83.0% | 21.9% | 46.5% | -25.6% | 3.2% | 9.7% | 16.9% | -25.0% | 2.2% | -3.7% |
| Net income growth (YoY) | - | 26.1% | 17.9% | -42.6% | 7.8% | 19.7% | 16.7% | -44.8% | 13.1% | 1.3% |
| EPS growth (YoY) | - | 28.8% | 19.0% | -42.2% | 8.3% | 23.5% | 20.9% | -55.6% | -9.4% | -19.8% |
| EPS CAGR (3y) | - | -14.7% | 10.0% | -17.5% | -29.0% | -8.4% | 15.7% | -39.2% | 3.3% | 31.4% |
| EPS CAGR (5y) | - | -20.7% | 10.1% | 9.7% | -1.2% | -2.6% | - | -18.1% | -12.0% | - |
| FCF growth (YoY) | - | -0.5% | - | - | -20.4% | - | - | 129.5% | - | - |
| FCF CAGR (5y) | - | -14.6% | - | - | 1.7% | - | - | 56.8% | - | - |
| Book value growth (YoY) | -4.4% | 0.3% | -1.9% | -1.6% | -0.5% | 0.4% | -0.2% | -0.5% | 2.0% | 4.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$8.02B totalMedical$4.58B · 57.1%
Life Sciences$1.87B · 23.3%
Interventional$1.57B · 19.6%
Geographic
$13.63B totalEMEA$4.73B · 34.7%
Asia$3.09B · 22.7%
US$2.79B · 20.5%
Non Us$1.79B · 13.1%
Others Country$1.23B · 9.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing BECTON DICKINSON & CO against the 5 most active filers in the same SIC group.
Dividends
$3.51/share trailing 12 months · +12.2% YoY
| Ex-date | Per share |
|---|---|
| Mar 10, 2026 | $1.0500 |
| Dec 8, 2025 | $0.8255 |
| Sep 8, 2025 | $0.8176 |
| Jun 9, 2025 | $0.8176 |
| Mar 10, 2025 | $0.8176 |
| Dec 9, 2024 | $0.8176 |
| Sep 9, 2024 | $0.7469 |
| Jun 10, 2024 | $0.7469 |
| Mar 7, 2024 | $0.7469 |
| Dec 7, 2023 | $0.7469 |
| Sep 7, 2023 | $0.7154 |
| Jun 8, 2023 | $0.7154 |
| Mar 9, 2023 | $0.7154 |
| Dec 8, 2022 | $0.7154 |
| Sep 8, 2022 | $0.6840 |
| Jun 8, 2022 | $0.6840 |
| Mar 9, 2022 | $0.6673 |
| Dec 9, 2021 | $0.6673 |
| Sep 8, 2021 | $0.6366 |
| Jun 8, 2021 | $0.6366 |
| Mar 9, 2021 | $0.6366 |
| Dec 9, 2020 | $0.6366 |
| Sep 8, 2020 | $0.6059 |
| Jun 8, 2020 | $0.6059 |